PRIVILEGED AND CONFIDENTIAL

INVESTIGATOR-SPONSORED RESEARCH AGREEMENT

This Research Agreement ("**Agreement**") is entered into as of the last date on the signature page hereof ("**Effective Date**"), by and between:

1. 3-D Matrix UK Ltd, a company whose registered office address is at [redacted], [redacted] co. number [redacted] ("**3-D Matrix**"),

2. **Všeobecná fakultní nemocnice v Praze**, with a place of business at U Nemocnice 499/2, 128 08 Prague 2, Czech Republic, Identification Number: [redacted] ("**Institution**"), represented by [redacted]; and

3. [redacted] ose address is [redacted] ("**Investigator**")

each a "**Party**" and together the "**Parties**".

WHEREAS

A. Institution and Investigator desire to conduct certain research activities involving PuraStat, a CE marked medical device marketed by 3-D Matrix (the "**Device**") according to the underlying research Project Plan ("**Project Plan**") which is attached in Schedule 1, as may be amended from time-to-time by written agreement of the Parties (the "**Research**");

B. Institution and Investigator have requested material from 3-D Matrix, including the supply of the Device for the Research;

C. 3-D Matrix has agreed to provide such support on the basis that Institution and Investigator shall conduct the Research independently and provide 3-D Matrix with access to Intellectual Property resulting from the Research;

D. This Agreement sets out the basis on which 3-D Matrix is prepared to provide support for the Research and to ensure that the Parties are able to comply with their obligations that arise as a result of the Research.

NOW, THEREFORE, THE PARTIES HAVE AGREED THE FOLLOWING:

1. CONDUCT OF RESEARCH AND DEVELOPMENT ACTIVITIES

1.1 The Research will be performed under the direction of Investigator and Institution or Investigator shall be the legal sponsor of the Research and will fulfil all requisite regulatory and legal duties and obligations in conducting the Research, including all duties as a 'sponsor' pursuant to the Clinical Investigation Regulations (as defined below).

1.2 Institution and Investigator may delegate duties and responsibilities to research staff only to the extent permitted by applicable laws, rules and regulations governing the Research and as far as it is ensured that the research staff is bound to the same confidentiality obligations and the Intellectual Property related obligations as stipulated in Clause 9 below. Institution and Investigator shall ensure that only individuals who are appropriately trained and qualified assist in the conduct of the Research, and shall ensure that all such individuals are informed about their obligations pursuant to this Agreement.

1.3 Institution and Investigator shall perform all aspects of the Research in accordance with:

(a) the terms of this Agreement;

(b) the Project Plan;

(c) the all laws, regulations, rules and standards applicable to clinical investigations of medical devices, including, without limitation, those set out in Council Directive 93/42/EEC concerning medical devices and national implementations thereof, Regulation (EU) 2017/745 on medical devices, EN ISO 14155:2020 on clinical investigation of medical devices for human subjects, International Conference on Harmonisation: Good Clinical Practice ("**ICH Guidelines**"), as well as all relevant guidance published by the European Commission and other regulatory authorities ("**Clinical Investigation Regulations**"),

(d) all applicable data protection and privacy legislation in force from time to time in the European Union ("**EU**"), including the General Data Protection Regulation (EU) 2016/679 ("**GDPR**"), and any other applicable EU relating to personal data ("**European Data Protection Legislation**");

(e) all other applicable laws and regulations; and

(f) the conditions of approval imposed by any competent ethics committee ("**EC**"), and any other regulatory authorities or other bodies, if any, whose review is required pursuant to applicable laws, regulations or institutional requirements.

1.4 Institution and Investigator certify that, to the best of their knowledge, Institution's facilities, products and any envisioned Research subject population are adequate to perform the Research contemplated by this Agreement and the Project Plan.

1.5 Subject to Clause 8, for the term of this Agreement, 3-D Matrix hereby grants to Institution and Investigator a fully paid-up, royalty-free, non-exclusive, non-transferable, non-sublicensable license to use the Device as necessary or useful to perform their obligations under this Agreement.

1.6 Institution and Investigator acknowledge and agree that 3-D Matrix will not provide any financial support to Institution and Investigator under this Agreement.

2. SUPPLY OF DEVICE

2.1 3-D Matrix will support the Research by providing the Device to Institution through 3-D Matrix's authorised representative in Czech Republic, MedVed PRAHA s.r.o., U Stavoservisu 659/3, 108 00, Praha 10. [redacted] (or as it shall direct) and necessary related materials (e.g. handling and storage instructions), free of charge and in quantities as agreed in Schedule 1. Institution shall be solely responsible for any re-labelling or re-packaging necessary to comply with any regulatory or EC requirements imposed on them in connection with the Research.

2.2 Institution shall maintain appropriate control of the Device. Institution shall use all Device supplied by 3-D Matrix only in the conduct of the Research as set forth in the Project Plan and for no other purpose whatsoever.

2.3 Institution shall comply with any operating and maintenance instructions for the Device provided by 3-D Matrix and shall store the Device under conditions that minimise the risk of loss or damage.

2.4 Institution shall maintain records of the use of all quantities of the Device supplied by 3-D Matrix and shall promptly return to 3-D Matrix (or as it shall direct) any Device not used in connection with the Research on expiry or earlier termination of this Agreement (unless 3-D Matrix authorizes Institution to destroy it or otherwise directs). 3-D Matrix shall have the right to conduct audits of Device usage during the Research at any time upon reasonable notice.

3. TECHNICAL SUPPORT

3-D Matrix agrees to provide Institution and Investigator with such technical support as Institution and Investigator reasonably require for the conduct of the Research which shall include the types of support set out in Schedule 3. It is acknowledged that any information provided as part of such support may include 3-D Matrix's Confidential Information (as defined in Clause 9).

4. REQUISITE APPROVALS AND INFORMED CONSENT

4.1 In requesting 3-D Matrix's support Institution and Investigator represent and warrant to 3-D Matrix that they have fulfilled to date and will continue to fulfil all obligations imposed by laws and regulations relevant to the conduct of the Research in the manner set forth in this Agreement and the Project Plan. Institution and Investigator acknowledge that such obligations include, but are not limited to:

(a) obtaining and maintaining all required regulatory authority and EC approvals for the Research For the avoidance of doubt, 3-D Matrix shall have no independent obligation to obtain regulatory authority or EC approval(s) for the Research;

(b) not infringing any intellectual property rights of any third party and not to use any such intellectual property of any third party that may impede 3-D Matrix from acquiring rights to the 3-D Matrix Improvements and Researcher Inventions (as defined in Clause 8.2);

(c) if the Research involves Research subjects, obtaining the written informed consent of all such subjects and complying with the European Data Protection Legislation; and

(d) complying with all medical device reporting and other obligations to the applicable regulatory authority;

4.2 Institution and Investigator will promptly notify 3-D Matrix in writing if any regulatory authority or EC withdraws or alters ay approval for this Research or withdraws or alters its approval of participation of Investigator in the conduct of the Research.

5. SAFETY REPORTING

5.1 Investigator shall promptly, and in any event within two (2) business days, notify 3-D Matrix of any information concerning any serious or unexpected side effect or other safety event or injury, and the severity thereof, caused by or associated with the Device or the Research.

5.2 Investigator shall be responsible for reporting information on safety events caused by or associated with the Research (including any relating to the Device) to the relevant regulatory authorities and ECs, in accordance with applicable laws.

6. REPORTS AND DELIVERABLES

6.1 Institution and Investigator will maintain accurate, complete and current records of their activities relating to the Research. A representative of 3-D Matrix may audit Institution's Research-related records only if required by relevant competent authorities and only to the extent necessary. 3-D Matrix will give Institution reasonable advance notice of any such audit, which will be conducted on Institution's premises during normal business hours.

6.2 Institution and Investigator will send to 3-D Matrix copies of any correspondence to or from any regulatory authority or EC regarding this Research or the Device within two (2) business days of receipt or transmittal.

6.3 Investigator shall have the following reporting obligations with respect to the Research:

(a) preparation and submission to 3-D Matrix of periodic progress reports every three (3) months, in email format; and

(b) attend meetings at least six (6) monthly (or such other times as the Parties may mutually agree) either in person or by video or telephone conference, with 3-D Matrix to discuss the progress of the Research;

(c) preparation and submission to 3-D Matrix of a written final Research report no later than six (6) months after Research completion.

7. PUBLICATION

7.1 Investigator shall be free to publish and present the results of the Research, subject to its obligations under this Agreement and applicable law. Investigator shall furnish 3-D Matrix with a copy of any proposed publication or presentation for review and comment not less than thirty (30) days prior to any presentation to any third party or submission for publication. In the event that a publication is accepted by a journal, Investigator shall notify 3-D Matrix of the same within five (5) days and provide 3-D Matrix a copy of the publication by email.

7.2 At the expiration of such thirty (30) day period, Investigator may proceed with the presentation or submission for publication; provided, however, that in the event 3-D Matrix has notified Investigator in writing that 3-D Matrix reasonably believes that prior to such publication or presentation it must take action to protect its confidentiality or intellectual property interests, such as the filing of a patent application claiming a 3-D Matrix Improvement as more fully described in Clause 8, Investigator shall either: (a) delay such publication or presentation for an additional forty-five (45) days or until the foregoing action(s) have been taken, whichever shall first occur; or (b) if Investigator is unwilling to delay the publication as set forth in (a), Institution and Investigator shall remove from the publication or presentation the information which 3-D Matrix has specified it reasonably believes would jeopardize 3-D Matrix. Investigator shall assist 3-D Matrix in obtaining reprints of the publication(s) resulting from the Research.

7.3 All documents, protocols, data, and confidential information (excluding Confidential Information provided by 3-D Matrix) generated in the performance of this Agreement ("Study Data") shall be considered the property of Institution.

7.4 Institution agrees, however, to provide 3-D Matrix with any and all Study Data, excluding personal data, upon request from 3-D Matrix, including copies of the final form of any manuscripts, posters, slide presentations or abstracts relating to the Study.

7.5 Institution also agrees to provide 3-D Matrix with a copy of the final clinical study report of the Research upon request from 3-D Matrix.

7.6 For the avoidance of doubt, 3-D Matrix may utilize or disclose the results of the Research in the form of final report, without being entitled to modify any of the Study Data, for any purpose including but limited to use in any internal research purposes, regulatory or patent filing or other submission to a regulatory authority in connection with the Device without the consent of Institution and Investigator.

7.7 3-D Matrix's support for this Research must be appropriately disclosed in the acknowledgement section of any publication(s) arising from or relating to this Research.

8. INTELLECTUAL PROPERTY

8.1 "**Intellectual Property**" means (i) the Study Data, (ii) all inventions, ideas, discoveries, developments, improvements and know-how, whether or not patentable or reduced to practice, (iii) all copyrightable works, such as reports, specifications, data, databases, software (source, object and executable code) and documentation, and (iv) all trade secrets and other intellectual property relating to any of the foregoing, such as copyrights; copyright registrations, renewals and applications; patents; patent applications; substitutions for, and divisions, continuations, extensions, continuations in part, renewals, reissues and reexaminations of, patents and patent applications, that are conceived, created, adopted, or developed by Researcher, whether made alone or in conjunction with others, whether or not conceived or made during working hours, and created or developed during the course of the Research, arising from or relating to the Research, derived from Confidential Information or the use of the Device or equipment.

8.1 The Parties agree that neither Party transfers to the other by operation of this Agreement any right in or licence to any patents, copyrights or other proprietary right owned as of the Effective Date of this Agreement or arising outside of the research conducted under this Agreement.

8.2 Institution and Investigator agree to disclose to 3-D Matrix all innovations, inventions and discoveries whether or not patentable or copyrightable, created, adopted or reduced to practice by or for Institution and Investigator, whether made alone or in conjunction with others, and arising from or relating to the Research ("**Researcher Inventions**"). Right and title to Researcher Inventions vest in Institution and Investigator; provided that (a) any such innovation, invention or discovery that is jointly created with employees of 3-D Matrix or other persons who have an obligation to assign their rights to 3-D Matrix ("**Joint Inventions**") will be jointly owned by 3-D Matrix and Institution and Investigator, and (b) any such innovation, invention, or discovery that constitutes an improvement to any Device provided to Institution under this Agreement for use under the Project Plan ("**3-D Matrix Improvement**") will be owned by 3-D Matrix. Institution and Investigator shall transfer, and shall ensure that all research staff shall transfer, all rights to such 3-D Matrix Improvements to 3-D Matrix. Institution and Investigator shall (i) assist 3-D Matrix, or anyone 3-D Matrix designates, to prepare, file, prosecute, issue and maintain patent applications or seek other protection relating to 3-D Matrix Improvements, and (ii) acknowledge, execute and deliver promptly to 3-D Matrix written instruments and do such other acts as may be necessary, in the opinion of 3-D Matrix, to file, obtain, maintain or reissue patents, patent applications, or other forms of protection relating to 3-D Matrix Improvements or Joint Inventions and to vest the ownership rights as specified in this Clause 8.2. Institution and Investigator shall take all reasonable steps to have each of those persons who has or will have participated in the performance of the Research execute any such written instruments required for such vesting of rights in 3-D Matrix. Each Party may exploit any Joint Invention with no duty to account to the other Parties.

8.3 Institution and Investigator hereby grant to 3-D Matrix a perpetual, irrevocable, fully paid-up, royalty-free, non-exclusive, non-transferable licence to use Researcher Inventions for its internal research. In addition, Institution and Investigator hereby grant to 3-D Matrix a right of first refusal to acquire the sole ownership rights to the Researcher Inventions or to acquire a worldwide,

exclusive or non-exclusive (at 3-D Matrix's sole option), transferable, irrevocable, royalty-bearing license, with the right to sublicense, to make, have made, use, sell, offer for sale, import and export products, methods or services embodying or based upon Researcher Inventions. Institution and Investigator agree to sign and deliver to 3-D Matrix any documents required to secure 3-D Matrix's rights under this Clause 8.3. Any license granted to 3-D Matrix under this Clause 8.3 assumes that 3-D Matrix's distributors and customers are entitled to purchase or procure products or services that embody or are based upon such intellectual property.

8.4 No Party will use any trademark, trade name, or other name or logo of another Party or the name of any of its employees for promotional or advertising purposes, nor issue any public statement concerning this Agreement, without written permission from the other Party.

9. CONFIDENTIALITY

9.1 Before and during the course of the Research, a Party may disclose certain confidential and/or proprietary information, including but not limited to the disclosing Party's proprietary materials and technologies, economic information, business or research strategies, trade secrets and material embodiments thereof (each Party's "**Confidential Information**"), to another Party solely for the purpose of carrying out the Research.

9.2 Throughout the term of this Agreement and for a period of five (5) years from the expiration or termination of this Agreement, the recipient shall maintain the disclosing Party's Confidential Information in confidence and shall not disclose such information to any third party. The recipient shall use the disclosing Party's Confidential Information solely for its performance of the Research and development activities, unless otherwise mutually agreed in writing.

9.3 The recipient's obligations of confidentiality and non-use under Clause 9.2 shall not apply to any information:

(a) that is shown by contemporaneous documentation of the recipient to have been in its rightful possession on a non-confidential basis prior to receipt from the disclosing Party;

(b) that is or becomes, through no (direct or indirect) fault of the recipient, publicly known;

(c) that is furnished to the recipient by a third party without breach of a duty of confidentiality to the disclosing Party or any other party;

(d) that is independently developed by the recipient without access to the disclosing Party's Confidential Information; or

(e) the disclosure of which is required by applicable law or by any court or applicable regulatory authority, provided that the disclosing Party has received advance notice of the proposed disclosure by the recipient.

10. LEGAL COMPLIANCE, ANTI-BRIBERY

10.1 Throughout the conduct of the Research, Institution and Investigator shall comply with all applicable laws and regulation, including anti-bribery or anti-corruption laws and regulations of the Czech Republic ("**Anti-Bribery Laws**"). Institution and Investigator represent and warrant that:

(a) no payment of money or benefit of any kind has been offered, promised, made, or given, whether directly or indirectly, to any person, whether or not a party to this Agreement and whether or not a government official, as an improper or corrupt inducement or reward in relation to the negotiation or execution of this Agreement; and

(b) they have not been the subject of any investigation, inquiry or enforcement proceedings by any governmental, administrative or regulatory body regarding any applicable Anti-Bribery Laws, and no such investigation, inquiry or proceedings have been threatened or are pending and there are no circumstances likely to give rise to any such investigation, inquiry or proceedings.

10.2 Institution and Investigator shall notify 3-D Matrix promptly upon becoming aware that they are under investigation for an actual or suspected breach of any Anti-Bribery Laws.

11. INDEPENDENCE OF RESEARCH

11.1 Institution and Investigator accept and acknowledge that they are solely responsible for the initiation, conduct and management of the Research and that he does so entirely independently of 3-D Matrix. 3-D Matrix shall not be responsible in any manner whatsoever for the initiation, conduct or management of the Research or for any use of the Device in the course of the Research and Institution and Investigator shall not indicate to any third party (including without limitation, any Research subject, regulatory authority, hospital or EC), that 3-D Matrix is in any manner responsible for the Research. Institution and Investigator acknowledge that 3-D Matrix shall have no liability (whether by indemnity or otherwise) to Institution and Investigator, any regulatory authority or hospital, or any agent of Institution in connection with the conduct of the Research.

11.2 Institution and Investigator declares that the Institution has taken out insurance according to § 45 Section 2 letter n) of the Act 372/2011 Coll., on healthcare service, as amended,, and shall provide evidence of such insurance to 3-D Matrix on request.

12. TERMINATION

12.1 This Agreement shall continue from the Effective Date until the date of completion of the Research in accordance with the Project Plan (as notified by Investigator to 3-D Matrix) subject always to earlier termination under this Clause 12. For purposes of this Agreement, the Research is considered complete after conclusion of all Project Plan-required activities for all enrolled subjects.

12.2 This Agreement may be terminated at any time if any of the following events occurs:

12.2.1 **No Regulatory Authority or EC approval**

If the Research is never initiated because of regulatory authority or EC disapproval or because the Institution and Investigator fail to obtain all necessary regulatory authority or EC approvals for the Research by 01/09/2022, this Agreement will terminate immediately upon the earlier of the occurrence of such disapproval or aforementioned date, respectively.

12.2.2 **Recruitment Failure**

3-D Matrix may terminate this Agreement immediately upon written notice to Institution and Investigator if Investigator fails to meet the Research subject recruitment target(s) set out in the Project Plan or otherwise agreed in writing between the parties by 01/09/2023.

12.2.3 **Research Abandonment**

If Investigator intends to end his participation in the Research before completion, Investigator must so notify 3-D Matrix thirty (30) days in advance. If an acceptable substitute investigator is not found within a reasonable time period, 3-D Matrix may terminate this Agreement upon written notice to Institution and Investigator.

12.2.4 **Material Breach**

If (i) 3-D Matrix or (ii) Institution or Investigator breaches any material provision of this Agreement, the other Party may terminate this Agreement upon thirty (30) days' written notice to the breaching Party; provided, however that if the breaching Party cures the breach within thirty (30) days of the receipt of such notice, this Agreement will continue in full force and effect.

12.2.5 **Termination by Any Party**

Any Party may terminate this Agreement upon immediate written notice to the other Parties if the authorization and approval to perform the Research is withdrawn by the EC or any applicable regulatory authority or if such termination is required to protect the health and safety of any Research subjects.

12.3 Upon termination of this Agreement (howsoever arising):

12.3.1 Institution shall return or destroy, at 3-D Matrix's discretion, any Device already received from 3-D Matrix hereunder that has not been used in connection with the performance of the Research;

12.3.2 Subject to Clauses 8 and 9, each Party shall cease using the other Parties' Intellectual Property and Confidential Information;

12.3.3 3-D Matrix shall have no obligations hereunder in respect of any further supply of the Device or technical support (if any).

12.4 Notwithstanding any other termination right set forth in this Agreement or in the applicable laws and regulations, the Institution reserves the right to terminate this Agreement at any time without cause upon one (1) month prior written notice.

13. TRANSPARENCY AND PUBLIC DISCLOSURES

13.1 Institution and Investigator agree that 3-D Matrix may, without prior consent, publicly disclose information about Institution and Investigator as required by applicable laws, including, but not limited to identifying Institution and Investigator as conducting the Research, and any support provided under this Agreement. Institution and Investigator further agree to provide, at 3-D Matrix's reasonable request, any information necessary for 3-D Matrix to make such disclosure.

13.2 Investigator shall comply with any requirements under applicable laws or institutional policies to notify this Agreement to or obtain approval from any regulatory authorities or professional associations and any other employers or institutions prior to performing the Research, and will do so on a timely basis. Evidence of such notifications and/or approvals shall be provided to 3-D Matrix upon request.

14. GENERAL

14.1 Survival

Any provision of this Agreement that expressly or by implication is intended to come into or continue in force on or after termination or expiry of this Agreement shall remain in full force and effect.

14.2 Status of Parties

Nothing in this Agreement shall be deemed to constitute a partnership, agency or joint venture relationship between the Parties and none of the Parties shall do or suffer to be done anything whereby it might be represented as a partner or agent of the other Parties. It is hereby acknowledged that nothing contained herein shall constitute or be deemed to constitute in any manner whatsoever a contract of employment. Each Party confirms it is acting on its own behalf and not for the benefit of any other person.

14.3 Entire Agreement

14.3.1 The Schedules form part of this Agreement and shall have effect as if set out in full in the body of this Agreement. Any reference to this Agreement includes the Schedules.

14.3.2 This Agreement embodies and sets forth the entire agreement and understanding of the Parties and supersedes all prior, oral or written agreements, understandings or arrangements (if any) relating to the Research.

14.4 Conflict

In the event of a conflict between any provisions of the main body of this Agreement and the Schedules, the provisions of this Agreement will govern, except in the case of matters relating directly to clinical procedures, with respect to which the provisions of the Project Plan will govern.

14.5 **Subcontracting**

Institution and Investigator shall not assign all or any part of their liabilities or obligations hereunder without the prior written consent of 3-D Matrix. Subject to the foregoing, prior to engaging any subcontractor, Institution and Investigator shall inform them of the confidentiality restrictions material to the engagement and enter into written contracts binding each subcontractor to terms no less strict than those in this Agreement. All such subcontractors shall be retained directly by Institution or Investigator and no contractual relationship or financial obligation shall be created between 3-D Matrix and any such sub-contractors. 3-D Matrix's consent to a subcontractor shall not in any way relieve Institution and Investigator of any duty or responsibility under this Agreement, and Institution and Investigator shall remain responsible for all acts and omissions of such subcontractor as if the acts or omissions were made by Institution and Investigator.

14.6 **Amendment**

This Agreement shall not be amended, modified, varied or supplemented except in writing signed by a duly authorized representative of 3-D Matrix, Institution and Investigator.

14.7 **Severability**

If any provision (or part thereof) of this Agreement is or becomes unenforceable, invalid or illegal for any reason it shall be deemed to deleted, but that shall not affect the validity and enforceability of the rest of the Agreement.

14.8 **Notices**

14.8.1 Any notices given under this Agreement shall be sufficiently served if in writing and sent to the address of the recipient Party as set out below:-

3-D Matrix: [redacted]

For the attention of: [redacted]

Institution: [redacted]

For the attention of:

Investigator: [redacted]

Provided that:-

(a) if served by hand (including courier) it will be deemed received when delivered; and

(b) if served by first class post it will be deemed received two (2) days after posting.

14.8.2 Any modification or amendment to the address of a Party must be notified in writing to the other Parties in accordance with the terms of this Clause 14.9.

14.9 **Counterparts**

This Agreement may be signed in one or more counterparts by authorized signatories of each Party, each of which counterpart when executed and delivered to the other Parties will be an original and all of which shall constitute one and the same Agreement.

14.10 **Governing Law and Jurisdiction**

14.10.1 This Agreement, and any dispute or claim arising out of or in connection with it or its subject matter or formation (including non-contractual disputes or claims) ("**Dispute**") shall be governed by and construed in accordance with the laws of the Czech Republic. The Parties irrevocably agree that the courts of the Czech Republic, shall be the exclusive place of venue for any Dispute.

14.10.2 Before taking recourse to legal remedies, the Parties shall use best efforts to settle amicably any dispute arising under this Agreement in good faith negotiations between business executives with authority to resolve controversy. Legal recourse can be pursued if the Parties cannot reach an amicable settlement agreement within thirty (30) days of the notification of the dispute. However, no Party shall be hindered to seek interim injunctive relief if such legal measure is deemed necessary to prevent serious or irreparable injury of a Party, its employees, affiliates, or agents.

The Parties hereto have entered into this Agreement by their duly authorised representatives.

SIGNED for and on behalf of

3-D MATRIX UK LIMITED

_____

Name: [redacted]

Title: [redacted]

SIGNED for and on behalf of

Všeobecná fakultní nemocnice v Praze

_____

Name: [redacted]
Title: [redacted]

SIGNED by Investigator:

[redacted]

_____